Full Press Release Details
cph8kex991022508.txt
--------------------------------------------------------------------------------
China Pharma Holdings, Inc. Receives $5.6 Million in Purchase
Orders for Pusen OK (Generic Aleve-D(TM) Product)
The Company announces unaudited preliminary 2007 revenue
of approximate $33 million, representing an over 50% increase from 2006
NEW YORK and HAIKOU CITY, Hainan Province, China, February 25, 2008 -- China
Pharma Holdings, Inc. ("China Pharma") (OTC BB: CPHI - News) which develops,
manufactures, and markets generic and branded bio-pharmaceutical products in
China, today announced it received new purchase orders from one of its main
distributors for its Pusen OK, a generic version of Aleve-D(TM). The orders
total approximately $5.6 million, are expected to be recognized during 2008 and
carry associated gross margins higher than 55 percent, which is approximately 10
percent higher than the Company's average gross margins during the past year.
Separately, the Company announced preliminary revenues for 2007 of at least $33
million, representing an over 50 percent growth compared to 2006. Pusen OK
contributed approximately $4.1 million in revenues during 2007.
Since mid January, several of the worst snowstorms in decades struck most of
central and southern China. As a result of this and other factors related to the
colder weather and lower temperatures in China, the incidence of flu and
cardiovascular diseases surged dramatically, and has increased the demand for
China Pharma's cold medicine Pusen OK, the only generic version of Aleve-D(TM)
brand with an antihistamine in China. Compared to other cold medicines in
China's market, Pusen OK is among the most effective with 12 hour relief and
does not cause sleepiness as a side effect.
Ms. Zhilin Li, president and CEO of China Pharma said: "I am very pleased to
announce this new order for our Pusen OK product as our focused sales and
marketing efforts have successfully created awareness among many of our major
pharmaceutical distributors. The Company recently initiated production to
fulfill these orders and anticipate initial contributions during the first
quarter. Further, we expect Pusen OK will be a significant contributor to our
growth during 2008, and will be supported by increased sales from our existing
product portfolio in addition to the launch of two new products during the first
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and
brand bio-pharmaceutical products in China that treat a wide range of
conditions, including infections, hepatitis, cardiovascular and CNS diseases,
and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a
specialty pharmaceutical company headquartered in Haikou City, Hainan province
in China, is a wholly owned subsidiary of China Pharma Holdings. For more
information about China Pharma Holdings, Inc., please visit
Safe Harbor Statement:
Certain statements in this press release and oral statements made by China
Pharma on its conference call in relation to this release, constitute
forward-looking statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Any statements set forth above
that are not historical facts are forward-looking statements that involve risks
and uncertainties that could cause actual results to differ materially from
those in the forward-looking statements, which may include, but are not limited
to, such factors as unanticipated changes in product demand, increased
competition, failure to obtain or maintain intellectual property protection,
downturns in the Chinese economy, uncompetitive levels of research and
development, failure to obtain regulatory approvals, and other information
detailed from time to time in the Company's filings and future filings with the
United States Securities and Exchange Commission. The forward-looking statements
made herein speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to conform the
statement to actual results or changes in the company's expectations.
China Pharma Holdings, Inc.
Sophia Yu, +86-898-6681-1730
HC International, Inc.
Alan Sheinwald, (914) 669-0222